Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

Categorical Exclusion Memo - Wilate, November 19, 2009

To: BLA STN 125251/0
From:Marion Michaelis, Reviewer, CBER/OCBQ/DMPQ/MRB2, HFM-676
To: John A. Eltermann, Jr., R.Ph., M.S., Director, DMPQ, HFM-670
Through:Chiang Syin, PhD, Branch Chief, CBER/OCBQ/DMPQ/MRB2, HFM-676
Subject:Memo - Categorical Exclusion under 21 CFR 25.31(c) for Biologics License Application (BLA) for von Willebrand Factor Concentrate (Human) [Wilate] manufactured at Octapharma Pharmazeutika Produktionsges.m.b.H - [License No. 1646], Vienna, Austria location.
Date:November 19, 2009

I have reviewed pertinent sections of the Biologics License Application (STN 125251/0) from Octapharma Pharmazeutika Produktionsges.m.b.H. for the manufacture of Coagulation Factor VIII/von Willebrand Factor Complex (Human), and find that the request for a categorical exclusion from an environmental assessment under 21 CFR 25.31(c) is justified because the product is composed of naturally occurring substances, the manufacture or use of the product will not alter significantly the concentration or distribution of the substance, its metabolites or degradation products, and no extraordinary circumstances exist.  This determination applies to all manufacturing locations associated with this application.



Marion Michaelis, Reviewer




Chiang Syin, PhD






John A. Eltermann, Jr., R.Ph., M.S.


Page Last Updated: 09/23/2013
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English